OMER — OMEROS CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1285819 ·
Last close
$19.32
Market Cap
$1.40B
52W High
$19.58
52W Low
$6.70
ADV30
2,142,258
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 9,893,000 | 9,306,000 | -17,421,000 | 56,060,000 | 286,173,000 | 1,906,000 | 349,507,000 |
| Dec 2025 | 0 | — | -29,081,000 | 86,451,000 | 325,632,000 | 9,660,000 | 446,863,000 |
| Sep 2025 | 0 | — | -26,392,000 | -30,917,000 | 185,706,000 | 2,395,000 | 406,184,000 |
| Jun 2025 | 0 | — | -32,354,000 | -25,424,000 | 200,569,000 | 1,904,000 | 429,254,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-94,759,000
Investing CF
$154,716,000
Financing CF
$-62,312,000
CapEx
$-91,000
Dividends Paid
—
Buybacks
$-4,152,000
EPS Diluted TTM
$0.70
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-857,635,000
Inventory
$183,000
Receivables
$37,509,000
ST Investments
$133,410,000
EBIT TTM
$-24,147,000
Pretax Income TTM
$86,076,000
Interest Exp TTM
$12,740,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$38,422,000
EBITDA
$-71,913,000
Free Cash Flow
$183,310,496
Enterprise Value
$1,563,459,328
Total Cash
$131,953,000
Total Debt
$296,870,016
Shares Out
72,388,316
Trailing EPS
$1.65
Book Value
$-0.71
ROE
—
ROA
-18.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,796,000 | -3,350,000 | 325,632,000 | 446,863,000 | — | -116,094,000 |
| Dec 2024 | 0 | -166,953,000 | -156,815,000 | 277,079,000 | 459,688,000 | — | -148,803,000 |
| Dec 2023 | 0 | -164,530,000 | -117,813,000 | 378,269,000 | 403,252,000 | — | 74,726,000 |
| Dec 2022 | 0 | -163,389,000 | 47,417,000 | 590,969,000 | 505,285,000 | — | -86,483,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$35,135,000
NetIncome TTM
$-58,342,000
OpCashFlow TTM
$0
Assets (Latest)
$116,328,000
Forward EPS
$1.15
Max Pain — expiry 2026-09-18
max pain strike: $15.00 · spot: $19.32 · call oi: 7,706 · put oi: 2,112
Expected Move to 2026-09-18:
±$2.40
(12.42%) —
implied range
$16.92 –
$21.72
· ATM straddle on $19.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AKTS | Aktis Oncology, Inc. | $1.40B | $25.98 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $1.40B | $13.46 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.39B | $28.26 | — |
| ANRO | Alto Neuroscience, Inc. | $1.42B | $36.25 | — |
| JBIO | Jade Biosciences, Inc. | $1.36B | $21.33 | — |
News headlines (Yahoo Finance, 1h cache)
Omeros (OMER) Q2 2026 Earnings Call Transcript
2026-08-20 00:13 · Yahoo
Omeros (OMER) Turns Profitable As Investors Ask If The Repricing Has Gone Too Far
2026-08-14 15:13 · Yahoo
Omeros Q2 Earnings Call Highlights
2026-08-13 01:04 · Yahoo
Omeros (OMER) Q2 Earnings and Revenues Beat Estimates
2026-08-12 21:20 · Yahoo
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return
2026-07-15 15:43 · Yahoo
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
2026-07-08 21:41 · Yahoo
Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?
2026-07-07 05:53 · Yahoo
Why Is OMER Stock Falling Today?
2026-06-26 12:33 · Yahoo
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
2026-06-26 12:30 · Yahoo
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
2026-06-22 14:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.